|Articles|October 26, 2006

XOMA and Affimed Sign Agreement

Author(s)BioPharm International Editors

XOMA Ltd. (Berkeley, CA, http://www.xoma.com) and Affimed Therapeutics AG (Heidelberg, Germany, www.affimed.com) have signed a cross-license and collaboration agreement for antibody-related technologies. The agreement provides XOMA with a license under Affimed’s antibody library patents for antibody discovery purposes, as well as for the development and commercialization of antibodies.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

Syracuse plant adds 40,000 liters of bioreactor capacity to Alvotech's supply chain as the biosimilar developer plans for future launches. Credit: Stock.Adobe.com/KHAN VECTOR CO.

October 7th, 2026

Alvotech Selects LOTTE Biologics' Syracuse Plant to Make Biosimilar Antibody Drug Substance

Alvotech turns to a CDMO's 40,000-liter Syracuse facility for biosimilar drug substance as it expands its manufacturing network.

October 6th, 2026

The BioPharm Brief: Advancing Parkinson, Kidney, Obesity and Cancer Care

New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.

AbbVie and Genmab say epcoritamab plus R-CHOP improved progression-free survival in newly diagnosed DLBCL; regulator talks are planned. Credit: Stock.Adobe.com/David A Litman.

October 6th, 2026

Epcoritamab Plus R-CHOP Improves Progression-Free Survival in Newly Diagnosed DLBCL in Phase 3 EPCORE DLBCL-2 Trial

Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.

After Part 1 maintenance data, Viking is testing oral tablets and less frequent injections to sustain weight loss from 21 weeks of weekly VK2735 dosing. Credit: Stock.Adobe.com/Daniel Krasoń

October 6th, 2026

Viking Begins Oral VK2735 Maintenance Trial in Obesity After Subcutaneous Dosing Data

Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.

Human Body Organs Anatomy (Liver with Kidneys): Image credit: © magicmine - © magicmine - stock.adobe.com

October 6th, 2026

CSL, Alentis Partner on Claudin-1 MAb Lixudebart for Kidney Disease

CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.

The X-ray of the human brain | Image credit: © merydolla - © merydolla - stock.adobe.com

October 6th, 2026

Alector, Genentech Ink Deal for Parkinson Therapy AL050

AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.

October 5th, 2026

The BioPharm Brief: Obesity Data and Manufacturing Shape Drug Progress

Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.

In 52-week phase 2 AMETHYST data, 27.2% of participants with cutaneous lupus reached clear or almost clear skin on litifilimab, up from 19.0% at week 24. (153 characters). Credit: Stock.Adobe.com/Love Employee

October 5th, 2026

Litifilimab Shows Sustained Skin Responses at 52 Weeks in Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus

Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.